| Hu, Yi |
NCT05649709: Helicobacter Pylori and Vonoprazan Dual Therapy |
|
|
| Completed | 4 | 504 | RoW | L-VA dual therapy, L-VA, H-VA dual therapy, H-VA | The First Affiliated Hospital of Nanchang University | Helicobacter Pylori | 01/24 | 01/24 | | |
public, NCT06162286: A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP |
|
|
| Recruiting | 3 | 100 | RoW | Omadacycline, Moxifloxacin | Zai Lab (Hong Kong), Ltd. | Community-acquired Bacterial Pneumonia | 01/25 | 11/25 | | |
TQB2450-AL2846-III-01, NCT05922345: Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy. |
|
|
| Recruiting | 3 | 518 | RoW | TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules, TQB2450 placebo, docetaxel injection, AL2846 matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non-small Cell Lung Cancer | 08/25 | 12/25 | | |
NCT05509699: Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 60 | RoW | Surufatinib, Anti-PD-1/L1, Immune checkpoint inhibitor | Hutchison Medipharma Limited | Extensive-Stage Small Cell Lung Cancer | 04/24 | 12/24 | | |
| Recruiting | 1/2 | 310 | RoW | ICP-723 | Beijing InnoCare Pharma Tech Co., Ltd. | Solid Tumors | 06/25 | 02/28 | | |
NCT06512051: A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 248 | RoW | SHR-A2102；Adebrelimab；Cisplatin/ Carboplatin | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced or Metastatic Non-small Cell Lung Cancer | 10/26 | 10/26 | | |
NCT04448379: Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 48 | RoW | JMT101, Afatinib or Osimertinib | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 12/21 | 06/22 | | |
NCT06349408: IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 250 | RoW | IBI3001 | Innovent Biologics (Suzhou) Co. Ltd. | Locally Advanced Solid Tumor | 12/26 | 12/27 | | |
NCT04368793: Clinical Effects of Internet Assisted Pulmonary Rehabilitation of COVID-2019 Pneumonia Patients After Discharge |
|
|
| Recruiting | N/A | 200 | RoW | Remote pulmonary rehabilitation | China-Japan Friendship Hospital, Wuhan lung Hospital, Wuhan central hospital, Wuhan University, Ai You Foundation | COVID-2019 Pneumonia, Pulmonary Rehabilitation | 12/20 | 12/21 | | |
NCT04853238: Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China |
|
|
| Completed | N/A | 1507 | RoW | Prospective observational cohort study | GlaxoSmithKline | Pulmonary Disease, Chronic Obstructive | 11/22 | 02/23 | | |
NOR-SPRINT, NCT05291819: Imaging Treat-to-target Strategy vs Conventional Treat-to-target Strategy in Psoriatic Arthritis |
|
|
| Recruiting | N/A | 202 | Europe | Imaging informed treat-to-target, Conventional treat-to-target | Diakonhjemmet Hospital | Psoriatic Arthritis | 12/27 | 12/27 | | |
NCT05824988: Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease |
|
|
| Recruiting | N/A | 100 | RoW | Drug exposure | Shanghai Pulmonary Hospital, Shanghai, China, Fudan University, University of Sydney, Karolinska Institutet, Shanghai Municipal Center for Disease Control and Prevention | Mycobacterium Avium Complex, Mycobacterium Avium-Intracellulare Infection, Gram-Positive Bacterial Infections, Mycobacterium Infections | 10/25 | 10/26 | | |
| Recruiting | N/A | 15000 | Europe | | Diakonhjemmet Hospital, University Hospital of North Norway, St. Olavs Hospital, Lillehammer Hospital for Rheumatic Diseases, Vestre Viken Hospital Trust, Helse Forde | Inflammatory Joint Diseases | 12/50 | 12/50 | | |
NCT05513664: Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | N/A | 80 | RoW | Osimertinib | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations | 06/23 | 08/23 | | |
